Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Unichem Labs gets...

    Unichem Labs gets USFDA nod for asthma drug

    Written by Ruby Khatun Khatun Published On 2018-07-06T10:30:10+05:30  |  Updated On 6 July 2018 10:30 AM IST
    Unichem Labs gets USFDA nod for asthma drug

    New Delhi: Drug firm Unichem Laboratories said it has received final approval from the US health regulator for its Montelukast chewable tablets used for prevention and treatment of asthma.


    The company has received final abbreviated new drug application (ANDA) approval from the United States Food and Drug Administration for generic Montelukast chewable tablets in the strengths of 4 mg and 5 mg, Unichem Laboratories said in a BSE filing.

    The product is a generic version of Merck Sharp & Dohme Corporation's Singulair tablets in the same strengths, it added.

    "The product will be commercialized from Unichem's Goa Plant," the company said.

    The tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients - 12 months of age and older, it added.

    They are also used in the treatment of seasonal allergic rhinitis in adults and patients - 2 years of age and older, and perennial allergic rhinitis in patients - 6 months of age and older, Unichem said.
    Abbreviated New Drug ApplicationANDAapprovalasthmaasthma drugfinal approvalgeneric versionMerck Sharp & Dohme CorporationMontelukast chewable tabletsperennial allergic rhinitisprophylaxisseasonal allergic rhinitisSingulair tabletsUnichem LaboratoriesUnichem LabsUnited States Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok